《新股消息》德琪医药(06996.HK)明日截招 孖展超购80倍现抽飞
德琪医药(06996.HK)明日截止招股,综合券商数据,累计录得孖展额逾227亿元,以公开发售部分集资2.78亿元计超购80倍。惟富途证券数据显示,借出孖展额由今早的逾67亿元降至约55亿元。
早前有消息指,德琪的国际配售部分已录得超额认购,提早一天於今日下午5时截飞。德琪医药料於本月20日挂牌上市。
融创服务(01516.HK)则录得约17.5亿元孖展认购额,超购约1.86倍。融创服务同於明日截止招股,计划於本月19日上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.